Article Information
History
- January 25, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Lichen Jing1,*,
- Xia Wu1,*,
- Maxwell P. Krist1,*,
- Tien-Ying Hsiang2,
- Victoria L. Campbell1,
- Christopher L. McClurkan1,
- Sydney M. Favors1,
- Lawrence A. Hemingway1,
- Charmie Godornes1,
- Denise Q. Tong1,
- Stacy Selke3,
- Angela C. LeClair1,
- Chu-Woo Pyo7,
- Daniel E. Geraghty7,
- Kerry J. Laing1,
- Anna Wald1,3,6,8,
- Michael Gale Jr.2,4,5 and
- David M. Koelle1,3,5,8,9,10
- 1Department of Medicine, University of Washington
- 2Department of Immunology, University of Washington
- 3Department of Laboratory Medicine and Pathology, University of Washington
- 4Center for Innate Immunity of Immune Disease, Department of Immunology, University of Washington
- 5Department of Global Health, University of Washington
- 6Department of Epidemiology, University of Washington
- 7Clinical Research Division, Fred Hutchinson Cancer Research Center
- 8Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center
- 9Benaroya Research Institute, Seattle
- ↵10Correspondence: David Koelle, 750 Republican Street, Room E651, Seattle, WA, 98109, 206 616 1940, dkoelle{at}medicine.washington.edu
↵* Contributed equally
Author Contributions Conceptualization: DMK, LJ, XW; Data curation and bioinformatic analysis: XW, LJ, MPK, DMK; Funding acquisition: MG, DEG, DMK; Investigation: LJ, XW, MPK, VLC, T-YH, CLM, C-WP, SMF, LH, CG, DT, KJL, DG; Data management: SS; Clinical protocol: AW, ACL; Supervision: DMK, MG; Writing: DMK, XW, MPK, LJ, KL.
Posted January 25, 2022.
T cell response to intact SARS-CoV-2 includes coronavirus cross-reactive and variant-specific components
